Key result
Non-ST elevation acute coronary syndromes were associated with significantly lower PAF EC50 values compared to healthy controls (p < 0.0001), yielding 91.2% sensitivity and 90.0% specificity.
Why the study?
Does ex vivo platelet aggregatory response to platelet activating factor (PAF) differ between patients with non-ST elevation acute coronary syndromes and healthy volunteers?
Population
32 consecutive patients with non-ST elevation acute coronary syndromes and 20 healthy volunteers (total n=52)
Comparison
Ex vivo platelet aggregation in response to… vs Healthy volunteers
Design
Case-control
Authors
Loading...
PAF EC50 may aid NSTE-ACS diagnosis but should not change practice; leaves open its causal role pending prospective studies.
Case-Control (n=52)
Does ex vivo platelet aggregatory response to platelet activating factor (PAF) differ between patients with non-ST elevation acute coronary syndromes and healthy volunteers?
p-value: p=< 0.0001
Platelet hyperaggregability to PAF is significantly increased in patients with non-ST elevation acute coronary syndromes, suggesting it may contribute to the pathophysiology of ACS.
Michalis et al. (2002) conducted a case-control in Non-ST elevation acute coronary syndromes (n=52). Non-ST elevation acute coronary syndromes vs. Healthy volunteers was evaluated on PAF EC50 values (concentration inducing 50% of maximal aggregation) (p=< 0.0001). Non-ST elevation acute coronary syndromes were associated with significantly lower PAF EC50 values compared to healthy controls (p < 0.0001), yielding 91.2% sensitivity and 90.0% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: